Many antifungal agents are available for the treatment of candidal infections, and these are available in several pharmaceutical forms for either topical or systemic use. The major agents belong either to the polyenes, such as amphotericin B and nystatin; or to the azoles, such as itraconazole and fluconazole. However, because of the need for extended treatment, the high cost, toxicity and limited action of the classic drugs, new and effective products are desirable to treat these fungal infections. The antifungal effect of essential oils (EO) of many aromatic plants has been described in several studies (9). The essential oils rich in cadinene isomers are widely reported to possess high levels of anticandidal activity (10). Our data indicate that the oil of C. officinalis flowers exhibited antifungal activity against all investigated yeasts, including the clinical pathogens obtained from reference stocks as well as those recently isolated. This oil provided more interesting results than Nystatin, a fungicide used for topical treatment of mucocutaneous candidiasis.